Valuation, from the filing
| Public float | $42.90B | Market value of stock held by non-affiliates, as stated on the cover page for 2025-06-30 |
|---|---|---|
| Float per share | $538.78 | Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself. |
| Float / net income | 40.5× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / revenue | 10.0× | A lower bound on the multiple, because affiliate holdings are excluded. |
| Float / equity | 26.7× | A lower bound on the multiple, because affiliate holdings are excluded. |
Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.
Valuation over time
40.5× earnings today, against a median of 48.3× across 10 years on record. Below its own history.
| Float measured | Public float | Float / net income | |
|---|---|---|---|
| 2025-06-30 | $42.90B | 40.5× | |
| 2024-06-30 | $40.08B | 45.1× | |
| 2023-06-30 | $41.33B | 48.9× | |
| 2022-06-30 | $28.96B | 42.7× | |
| 2021-06-30 | $53.42B | 71.7× | |
| 2020-06-30 | $27.74B | 47.7× | |
| 2019-06-30 | $23.37B | 54.6× | |
| 2018-06-30 | $18.70B | 49.6× | |
| 2017-06-30 | $14.01B | 53.2× | |
| 2016-06-30 | $8.22B | 37.0× |
Each float is paired with the fiscal year the filing that stated it covers. Only years where the company reported positive net income appear, because a multiple against a loss is not a multiple.
How this compares in its industry
Percentile among the In Vitro & In Vivo Diagnostic Substances filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.
| Measure | Reported | Percentile | |
|---|---|---|---|
| FCF margin | 24.6% | 100th | |
| Net margin | 24.6% | 100th | |
| Operating margin | 31.6% | 100th | |
| SBC / revenue | 1.4% | 8th | |
| Current ratio | 1.23x | 13th | |
| R&D / revenue | 5.8% | 15th | |
| Long-term debt / equity | 0.23x | 17th | |
| CapEx / revenue | 2.9% | 22th | |
| Revenue YoY growth | 10.4% | 71th | |
| Gross margin | 61.8% | 67th |
IDEXX LABORATORIES INC /DE (IDXX) reported revenue of $4.55B and net income of $1.14B for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from IDEXX LABORATORIES INC /DE’s SEC filings, each linked to the filing it came from. It is classified by the SEC under In Vitro & In Vivo Diagnostic Substances.
Income
| Metric | 2026-06-30 |
|---|---|
| Revenue | $4.55B |
| Cost of revenue | $1.71B |
| Gross profit | $2.84B |
| Operating income | $1.46B |
| Net income | $1.14B |
| Research & development | $261.46M |
| Weighted-average diluted shares | Unavailable |
| Pretax income | $1.42B |
| Income tax expense | $284.76M |
| Diluted EPS | Unavailable |
| Selling, general & administrative | $1.12B |
| General & administrative | $450.48M |
| Selling & marketing | $672.74M |
Balance
| Metric | 2026-06-30 |
|---|---|
| Cash & equivalents | $196.93M |
| Total assets | $3.44B |
| Current assets | $1.51B |
| Total liabilities | $1.83B |
| Current liabilities | $1.29B |
| Total equity incl. NCI | $1.61B |
| Temporary (mezzanine) equity | Unavailable |
| Inventory | $391.58M |
| Accounts receivable | $627.08M |
| Goodwill | $410.95M |
| Long-term debt | $299.86M |
| Accounts payable | $129.10M |
Cash flow
| Metric | 2026-06-30 |
|---|---|
| Operating cash flow | $1.37B |
| Capital expenditures | $117.18M |
| Investing cash flow | -$132.04M |
| Financing cash flow | -$1.21B |
| Net change in cash | $32.34M |
| Stock-based compensation | $62.97M |
| Common dividends paid | Unavailable |
| Common share repurchases | $1.18B |
| Depreciation & amortization | $154.08M |
Derived
| Metric | 2026-06-30 |
|---|---|
| Free cash flow | $1.25B |
| Gross margin | 62.4% |
| Operating margin | 32.0% |
| FCF margin | 27.5% |
| SBC / revenue | 1.4% |
| Current ratio | 1.17x |
| Revenue YoY growth | 12.8% |
| Net margin | 25.0% |
| R&D / revenue | 5.7% |
| CapEx / revenue | 2.6% |
| Long-term debt / equity | 0.19x |
| Effective tax rate | 20.0% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IDXX in the interactive workspace to inspect any figure back to its filing.
Source filings
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.